Ben Bronstein
Direttore/Membro del Consiglio presso ALDEYRA THERAPEUTICS, INC.
Patrimonio netto: 111 297 $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Todd Brady | M | 52 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 19 anni |
Richard Douglas | M | 71 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 anni |
Gary Phillips | M | 58 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 15 anni |
Irene P. McCarthy | F | 59 | 9 anni | |
Bruce Greenberg | M | 56 | 5 anni | |
Jesse I. Treu | M | 76 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 9 anni |
Arnon Chait | M | - |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | 11 anni |
Nancy Miller-Rich | F | 65 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 4 anni |
Martin Joyce | M | 70 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 11 anni |
James A. Gow | M | - | 4 anni | |
Dean Eliott | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 anni |
Boris Zaslavsky | M | - |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | 11 anni |
Lin-Tsing Yu | M | 80 | 15 anni | |
Neal Walker | M | 54 | 11 anni | |
Sameer Rohatgi | M | - |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | - |
Johannes Nielsen | M | - |
Sentien Biotechnologies, Inc.
Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | 8 anni |
Aimee Kestranek | F | - |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | - |
Eli Arad | M | 51 |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | - |
Akhil Saklecha | M | - |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | - |
Brian Blakey | M | 61 | 10 anni | |
James R. Carr | M | 61 | 10 anni | |
Levi Kushnir | M | - |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | - |
Arthur Anton | M | 66 |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | - |
Stephen Machatha | M | 47 | 3 anni | |
Neil Walker | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
Kelly Mizer | M | - | 3 anni | |
Caitlin Pazzano | F | - | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stephen Tulipano | M | 65 | 4 anni | |
Daniel Behr | M | 65 |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | 2 anni |
Louis J. Arcudi | M | 63 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 7 anni |
Joshua Reed | M | 51 | 4 anni | |
Thomas Mathers | M | 56 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 8 anni |
Carole Cassidy | F | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 6 anni |
Mary E. Taylor | F | 65 | - | |
David H. Schubert | M | - | 6 anni | |
S. James Freedman | M | 57 | - | |
Uday Patel | M | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 7 anni |
Nicolas Mourier | M | 46 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 3 anni |
Eric H. Zanelli | M | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 8 anni |
Isaac Kohlberg | M | 71 |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | - |
Scott L. Young | M | 60 | 5 anni | |
David Noskowitz | M | - | 2 anni | |
Bernice Kuca | F | 65 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 2 anni |
David McMullin | M | - | 3 anni | |
Mark J. Bamberger | M | 71 | 6 anni | |
Steven E. Hyman | M | 71 |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | - |
Julie Krop | M | 57 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 3 anni |
Dustan Bonnin | M | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 8 anni |
David J. Clark | M | 59 | 4 anni | |
Jessica Willow Barnes | M | - |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | - |
Richard Straube | M | 72 | 5 anni | |
Mark P. Colonnese | M | 68 | 1 anni | |
Frank P. Pinto | M | - |
Zero Stage Capital Co., Inc.
Zero Stage Capital Co., Inc. Investment ManagersFinance Founded in 1981, Zero Stage Capital Co., Inc. is a venture capital firm headquartered in Cambridge, Massachusetts. | 2 anni |
Alan Walts | M | 64 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | - |
Naveed Shams | M | 67 | 1 anni | |
Robert Carpenter | M | 79 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 5 anni |
C. Boyd Clarke | M | 74 | 4 anni | |
Fredric D. Price | M | 78 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 4 anni |
William H. Koster | M | 79 |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | - |
Bic Stevens | M | - |
Zero Stage Capital Co., Inc.
Zero Stage Capital Co., Inc. Investment ManagersFinance Founded in 1981, Zero Stage Capital Co., Inc. is a venture capital firm headquartered in Cambridge, Massachusetts. | 2 anni |
Nader Yaghoubi | M | - |
Zero Stage Capital Co., Inc.
Zero Stage Capital Co., Inc. Investment ManagersFinance Founded in 1981, Zero Stage Capital Co., Inc. is a venture capital firm headquartered in Cambridge, Massachusetts. | 2 anni |
Asish Xavier | M | - | 9 anni | |
Ed J. Wang | M | - |
Zero Stage Capital Co., Inc.
Zero Stage Capital Co., Inc. Investment ManagersFinance Founded in 1981, Zero Stage Capital Co., Inc. is a venture capital firm headquartered in Cambridge, Massachusetts. | 3 anni |
Hidde L. Ploegh | M | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | - |
Michelle Tauberman | F | - |
Zero Stage Capital Co., Inc.
Zero Stage Capital Co., Inc. Investment ManagersFinance Founded in 1981, Zero Stage Capital Co., Inc. is a venture capital firm headquartered in Cambridge, Massachusetts. | - |
Manuel A. Navia | M | 77 |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | - |
Samuel Reich | M | 49 | 1 anni | |
Michael Reich | M | 81 | 2 anni | |
Jose-Carlos Gutiérrez-Ramos | M | 61 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | 6 anni |
Christine Blumhardt | M | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | - |
Michael Barrett | M | 81 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | - |
Luke Evnin | M | 60 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | - |
Jack L. Strominger | M | - |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 73 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ben Bronstein
- Contatti personali